On September 27 – October 1, 2019 our Urologic Oncologists in Barcelona, Spain at the European Society for Medical Oncology Conference. The ESMO Congress brings together clinicians, researchers, patient advocates, journalists, and pharmaceutical industries from all over the world to learn about the latest advances in oncology and translational science to improve cancer patient care.
Przemyslaw Twardowski M.D., Professor of Medical Oncology and Urologic Oncology at the John Wayne Cancer Institute, is the lead author in collaboration with Genocea on the poster, 1178PD – “A phase 1 trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumor mutations.”
Dr. Twardowski, is also the coauthor on a groundbreaking abstract, LBA12 that was presented at the Presidential Symposium on September 30th, 2019. The presentation, “PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations (ID 5059)”, discussed the results of a clinical trial that revealed that olaparib (PARP inhibitor class agent) extended time to disease progression in patients with certain genetic mutations of very advanced metastatic prostate cancer.